Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- Gov't Has Not Yet Considered Postponing Medical, Nursing Fee Revision in 2012: Senior Vice Minister Ohtsuka
May 16, 2011
- Pfizer Allows Special Leave for Volunteers in Disaster Area
May 16, 2011
- Korosho to Create Council on Regulatory Strategies
May 16, 2011
- Discussion Starts to Revise Ethical GL for Genome Analysis
May 16, 2011
- Supreme Court Favors Patent Extension for Takeda's DDS Formulations
May 16, 2011
- Korosho Draws Up Draft Guidance for Risk Management Plans
May 16, 2011
- Kaketsuken, GSK Start PI Trial of New Cell Culture-based Flu Vaccine
May 16, 2011
- Sawai, Takeda Take Actos Patent Dispute to IP High Court
May 16, 2011
- Long-Acting ESA Mircera Approved: Chugai
May 16, 2011
- Korosho Invites Medical Societies to Present Views on 10 Switch OTC Drug Candidates
May 16, 2011
- DSP Licenses Novel Topical Analgesic to Maruho
May 16, 2011
- Glubes Approved for Type 2 Diabetes: Kissei
May 16, 2011
- Sato Pharm. Launches Switch OTC Version of Clotrimazole for Vaginal Candidiasis
May 16, 2011
- Takeda Announces Equity Investment in Fate Therapeutics of US
May 16, 2011
- Once-Daily Mirapex Approved for Parkinson's Disease: NBI
May 16, 2011
- Daiichi Sankyo to Launch AD Treatment MEMARY in June
May 16, 2011
- Pancreatic Digestive Enzyme LipaCreon Approved: Abbott Japan, Eisai
May 16, 2011
- Mitsui to Acquire Mercian's Pharma and Chemicals Business
May 2, 2011
- Drug Price Listings to Be Delayed One Month: Korosho
May 2, 2011
- OECD Japan Report Calls For Restraint in Social Security Spending
May 2, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…